Uppsala, Sweden, 2014-09-01 08:57 CEST (GLOBE NEWSWIRE) --
Anders has more than 15 years of experience from international strategic business development and finance at Q-Med and Pharmacia. He has a Master of Business Administration degree from Uppsala University and he is currently CEO of Nexttobe AB where he will continue to have certain responsibilities.
As a new Executive Vice President, Anders will primarily focus on Oasmia’s business development. He will be succeeding Hans Sundin who leaves his position and who is nominated to become a new member of the Board of Oasmia Pharmaceutical AB. In addition to the task of being a Board member, Hans will also be participating in the company’s strategic production project and quality issues from a general perspective.
“I am very happy to welcome Anders to the company. His experience and knowledge will be most valuable at this stage of development of the company. At the same time it is my conviction that the future work of Hans as a Board member will contribute as an excellent and fundamental complement to the existing competence within the Board,” the CEO of the company, Julian Aleksov, commented this reorganization.
Anders’ new employment starts on October 1, 2014.
Om Oasmia Pharmaceutical AB
(NASDAQ OMX: OASM) Oasmia Pharmaceutical AB utvecklar en ny generation av läkemedel inom human- och veterinär onkologi. Produktutvecklingen syftar till att framställa nya formuleringar innehållande nanopartiklar av väletablerade cytostatika som i jämförelse med befintliga alternativ har förbättrande egenskaper, förbättrad biverkningsprofil samt bredare användningsområden. Produktutvecklingen bygger på egen forskning inom nanoteknik och egna patent. Bolagets aktie är noterad på NASDAQ OMX i Stockholm och på Frankfurt Stock Exchange.
Mikael Widell, Vice President Communications
Mobile: +46 70 311 99 60
E-mail: mikael.widell@oasmia.com
